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Abstract 
Carbamylation of lysine residues and protein N-termini is a ubiquitous, non-
enzymatic post-translational modification. Carbamylation at sites of inflammation is 
due to cyanate formation during the neutrophil oxidative burst and may target lysine 
residues within the antimicrobial peptide LL-37. The bactericidal and 
immunomodulatory properties of LL-37 depend on its secondary structure and 
cationic nature, which are conferred by arginine and lysine residues. Therefore, 
carbamylation may affect the biological functions of LL-37. The present study 
examined the kinetics and pattern of LL-37 carbamylation to investigate how this 
modification affects the bactericidal, cytotoxic, and immunomodulatory function of 
the peptide. The results indicated that LL-37 undergoes rapid modification in the 
presence of physiological concentrations of cyanate, yielding a spectrum of diverse 
carbamylated peptides. Mass spectrometry analyses revealed that the N-terminal 
amino group of Leu-1 was highly reactive and was modified almost instantly by 
cyanate to generate the predominant form of the modified peptide, named LL37C1. 
This was followed by the sequential carbamylation of Lys-8, Lys-12, and Lys-15, to 
yield LL37C8, and LL37C12,15, respectively. Carbamylation had profound and diverse 
effects on the structure and biological properties of LL-37. In some cases, anti-
inflammatory LL-37 was rapidly converted to pro-inflammatory LL-37. 
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Introduction 
Post-translational modifications (PTMs) are pivotal steps in protein maturation. PTMs 
increase the functional diversity of the proteome and play a key role in multiple 
cellular processes, including protein-protein interactions, cell signaling, 
differentiation, and regulation of gene expression [1]. Carbamylation is a ubiquitous, 
non-enzymatic PTM, in which cyanate (OCN−) reacts with primary amino groups 
(NH3+) at the N-termini of proteins, and with lysine residues in the polypeptide chain, 
to generate a protein:homocitrulline complex [2,3]. Since urea (a by-product of 
protein metabolism) and cyanate comprise an equilibrium pair, the level of protein 
carbamylation is markedly increased in diseases associated with chronic uremia (renal 
dysfunction). A recent study identified a novel pathway linking inflammation, 
myeloperoxidase (MPO), and carbamylation. MPO, a heme peroxidase released by 
activated neutrophils, catalyzes the formation of cyanate from hydrogen peroxide and 
thiocyanate, ultimately leading to homocitrullination of proteins [3]. The chemical 
conversion of positively charged Lys residues to neutral homocitrulline residues 
affects the charge distribution within a polypeptide chain in a manner that often 
results in impairment or even loss of function. For example, loss of function upon 
carbamylation has been reported for matrix metalloproteinase-2, inhibitor of 
metalloproteinase-2, and insulin [4,5]. 
The abundance of MPO at inflammatory foci has sparked significant interest 
in the role of carbamylation in the context of chronic inflammatory diseases and 
atherogenesis [3,6,7]. Apart from directly affecting protein function and turnover, 
homocitrulline residues act as neo-epitopes that can trigger primary immune 
responses, thereby inducing chemotaxis and proliferation of CD4+ T cells and the 
subsequent production of interferon-γ, interleukin (IL)-10, and IL-17. In addition, 
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antibodies against carbamylated residues have clinical value in that they predict a 
more erosive progression of rheumatoid arthritis [8,9]. 
Cationic antimicrobial peptides (CAMPs) are essential components of human 
innate immunity and are produced by a variety of cells, including epithelial cells [10], 
keratinocytes [11], and neutrophils [12]. In humans, CAMPs are represented by α- 
and β-defensins and the cathelicidin-derived LL-37 peptide. The active form of LL-37 
is characterized by a high abundance of arginine and lysine residues, which generate a 
net positive charge of +6 at a neutral pH. Apart from killing a wide spectrum of 
pathogenic bacteria [13,14], LL-37 neutralizes lipopolysaccharide (LPS), functions as 
a chemoattractant for immune cells (including T cells, monocytes, neutrophils, and 
mast cells)[15,16], profoundly affects the course of dendritic cell maturation [17], 
stimulates production of cytokines, chemokines, and their receptors [18,19], and 
triggers mast cell degranulation [16]. These effects are mediated, at least in part, by 
activation of at least four different receptors: formyl peptide receptor-like 1 (FPRL1), 
epidermal growth factor receptor (EGFR), P2X7, and CXCR2. Finally, recent studies 
show that LL-37 has a direct effect on the cells and might be hemolytic [20] or 
cytotoxic to peripheral blood mononuclear cells (PBMCs) at high concentrations [21]. 
At low concentrations (<5 μM), LL-37 induces rapid secondary necrosis of apoptotic 
human neutrophils [22]. To prevent collateral tissue damage due to exacerbation of 
inflammation, the activity of LL-37 is strictly controlled by serum proteins [23], most 
likely apolipoprotein-A1 (apoA-1) [24]. Taken together, all available data indicate 
that the antibacterial activity of LL-37 is secondary to its immunomodulatory 
functions. In a twist of the paradigm, it is now generally accepted that the major role 
of CAMPs is not direct killing of invading microbes, but rather acting as signaling 
molecules for innate and acquired immunity. 
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Within the inflammatory milieu, the concomitant release of LL-37 and MPO by 
activated neutrophils may create conditions required for LL-37 carbamylation. 
Additionally, lysine residues within CAMPs are crucial for peptide structure and 
activity, and conversion of these positively charged residues to neutral homocitrulline 
residues would be expected to abrogate the biological activity of LL-37. 
Here, we performed mass spectrometry based sequence analysis and found that 
LL-37 undergoes rapid carbamylation in the presence of cyanate in a time- and 
concentration-dependent manner. Unexpectedly, we found that the free amino group 
of the N-terminal leucine was most susceptible to carbamylation under conditions that 
reflected the cyanate concentration in the inflammatory milieu. Prolonged incubation 
resulted in the generation of a mixture of variably carbamylated LL-37 molecules 
with impaired antimicrobial activity against both Gram-negative and Gram-positive 
species. 
Taken together, these results suggest that carbamylation of LL-37 within an 
inflammatory environment might actually exacerbate inflammation and be 
detrimental to the host.  
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Materials and methods 
In vitro carbamylation of LL-37 and mass spectrometry analysis. LL-37 
(ProImmune, Oxford, U.K) was carbamylated by incubation with 10, 50 and 100 mM 
KCNO (Sigma-Aldrich, Oslo, Norway) in 100 mM HEPES (pH 7.8) for 3 hours at 
37°C. The reaction was quenched by addition of formic acid to a final concentration 
of 5% and samples were immediately purified using StageTips (ThermoScientific). 
The samples were lyophilized and either analyzed directly by LC-MS/MS or 
subjected to proteolytic digestion with S. aureus protease V8 (1:25 w/w) at 37°C for 
16 hours prior to LC-MS/MS analysis. NanoESI-MS/MS analyses were performed on 
an EASY-nLC II system (ThermoScientific) connected to a TripleTOF 5600 mass 
spectrometer (AB Sciex) equipped with a NanoSpray III source (AB Sciex) operated 
under Analyst TF 1.5.1 control. The samples were suspended in 0.1% formic acid, 
injected, trapped and desalted on a Biosphere C18 column (5 μo, 2 cm x 100 μ  I.D; 
Nano Separations) after which the peptides were eluted from the trap column and 
separated on a 15-cm analytical column (75 μI i.d.) packed in-house in a pulled 
emitter with RP ReproSil-Pur C18-AQ 3 μC resin (Dr. Marisch GmbH, Ammerbuch-
Entringen, Germany) and connected in-line to the mass spectrometer. The peptides 
were eluted using a 20 min gradient from either 5%–35% phase B or 5–90% phase B 
(0.1% formic acid and 90% acetonitrile). The collected MS files were converted to 
Mascot generic format (MGF) using the AB SCIEX MS Data Converter beta 1.1 (AB 
SCIEX). The peptide sequence was identified using in-house Mascot search engine 
(matrix science). Search parameters were allowing two missed cleaving sites and 
carbamylation as a variable modification. Peptide tolerance and MS/MS tolerance 
were set to 10 ppm and 0.1 Da respectively. 
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Peptide synthesis. Native and carbamylated LL-37 were synthesized by ProImmune 
by using Fmoc solid-phase peptide synthesis, diluted in 0.01% v/v acetic acid and 
stored at -70°C until use.  
Circular dichroism (CD) spectroscopy. The secondary structure of the LL-37 
analogues was investigated by Circular dichroism (CD) spectroscopy. The 
experiments were performed using a Jasco J-810 spectropolarimeter. Far UV-spectra 
were acquired at 37°C in the 195 – 260 nm range at a scan rate of 50 nm/min and a 
band width of 1 nm. Three scans were accumulated for each sample and appropriate 
blanks were subtracted from each spectrum by using the software provided by the 
instrument manufacturers. The peptides (10 µM) were analyzed upon dilution in a 10 
mM sodium phosphate buffer containing 50% v/v trifluorethanol (TFE) or a 
physiological salt solution resembling plasma (113 mM NaCl, 24 mM NaHCO3, 0.6 
mM MgCl2, 1.3 mM CaCl2, 3.9mM KCl) in 1.0-mm quartz cuvettes (Hellma-
Analytics, Oslo, Norway). The mean ellipticity was calculated using the formula [θ] = 
θ/(10·c·l), where θ is the ellipticity (mdeg), 10 is a scaling factor, c is the protein 
concentration (M) and l is the path length of the cuvette (cm). The helical content 
(percentage of helix) was estimated by using the CDNN program from the molar 
ellipticity θ [deg.cm2 dmol-1]. 
Broth microdilution assay. Frozen samples of S. aureus LS-1, E. coli ATCC 25922 
and B. subtilis ATCC 3366 were cultured on horse blood-agar plates at 37°C over 
night. Few colonies were selected and pre-cultured in 50 ml LB-broth in a shaking 
incubator (220 rpm, 37°C) over night. The bacteria were diluted 1:100 times in fresh 
LB-broth and cultured to its mid-log-phase. The bacteria were washed four times at 
4000 x g for 5 min (E. coli and S. aureus) or at 6000 x g for 8 min (B. subtilis) at 4°C 
and thereafter suspended to 1 x 106 CFU/ml in PBS without calcium and magnesium. 
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Native and carbamylated LL-37 described above were diluted in 0.01% v/v acetic 
acid containing 0.2% w/v bovine serum albumin (Sigma-Aldrich). Thereafter, one 
part of the peptide solutions were mixed with nine parts bacteria solution to get a final 
peptide concentration of 1 μg/ml (i.e., 0.2 μM). In addition, one positive control 
sample containing bacterial solution without additives and one negative control 
without bacteria were prepared. All samples were incubated for 2 hours at 37°C. 
Samples containing B. subtilis were incubated on a shaking plate at 220 rpm. 100 μl 
aliquots of the bacterial mixture were spread on blood agar plates in duplicate or 
triplicate after being 10-fold diluted in 4 steps (undiluted, 1:10, 1:100, 1:1000, 
1:10000). The plates were incubated at 37°C over night. Colony-forming units were 
counted and the total number was determined from the dilution factor. The 
experiments were performed under sterile conditions. 
Culture of human monocyte-derived macrophages (hMDMs). Human blood 
samples were collected from healthy volunteers by using heparin-coated tubes (BD) 
and diluted 1:1 in PBS without calcium and magnesium. PBMCs were isolated by 
density gradient separation on Lymphoprep (Axis-Shield Poc AS) and diluted in 
macrophage medium (RPMI 1640 containing UltraGlutamin supplemented with 10% 
v/v autologous human serum and penicillin streptavidin; Sigma-Aldrich). 
Subsequently, 3 x 106 cells/well were plated in 24-well plates (Sarstedt, Nümbrecht, 
Germany) and incubated for 24 hours at 37°C in 5% CO2. Non-adherent PBMCs were 
removed by washing with PBS. Adherent cells were cultured in regularly changed 
macrophage medium for a minimum of 10 days, at which time approximately 10% of 
the cells had differentiated into human monocyte-derived macrophages (hMDMs). 
Cytokine production of hMDMs. Following washing (3x) with PBS mature 
hMDMs were incubated with RPMI medium containing 0.5 µM native or 
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carbamylated LL-37 together with 100 ng/ml E-coli LPS (Sigma-Aldrich) in 
triplicated wells for 20 hours at 37°C in 5% CO2. RPMI without any additives was 
used as a negative control and RPMI with LPS was used as a positive control. The 
supernatants were removed from the wells, centrifuged at 300 x g for 5 min and 
frozen at -70°C until cytokine analysis. The concentrations of GM-CSF, IFN-γ, IL1β, 
IL-2, IL-4, IL-5, IL-6, IL-8, IL-10 and TNF-α were measured using a cytokine human 
10-plex panel (Life technologies, Oslo, Norway).  
Hemolysis of erythrocytes. Peripheral blood was collected in heparin coated tubes 
(BD) from healthy volunteers and centrifuged at 800 x g for 10 min at 10°C. The 
pellet was gently suspended in PBS, twice the original volume, and washed (2x) by 
centrifugation. The pellet was once again suspended in PBS to the initial blood 
volume. Thereafter, 4% v/v erythrocyte suspension was mixed with 1-20 µM native 
and carbamylated LL-37 diluted in PBS, added to a V-bottomed 96-well plate and 
incubated for 1-6 hours at 37°C. The plate was mixed every 15 min by shaking at 600 
rpm. After incubation, the plates were centrifuged at 500 x g for 5 min. The 
supernatant was collected and the released of hemoglobin was measured at 405 nm. 
Chemotaxis of neutrophils. The Insall chamber was used to visualise chemotaxis 
[25]. For each sample, discontinuous Percoll gradient isolated neutrophils (400 μl in 
RPMI, final density 1 × 106/ml) were added to acid washed (0.2 M HCl), dried and 
blocked (7.5%, BSA 400 μl, Sigma) coverslips (22 mm, VWR International), which 
were then incubated at room temperature (approximately 23°C) for 30 min. to allow 
the cells to adhere. The coverslip was then inverted and placed at the top of the 
chemotaxis chamber ensuring that the chemoattractant loading bays were exposed. 
The desired chemoattractant (80 µl), fMLP (10 nM) or LL-37 and its modified forms 
(used at 20 µM after assessing a range of concentrations) or control (RPMI media) 
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was injected into the chemoattractant channels. The cell movement was analyzed 
using a Zeiss Primovert microscope (Carl Zeiss Imaging, Thornwood, NY, USA) and 
Images captured every 30 s for up to 40 frames per condition using a Q Imaging 
Retiga 2000R camera (Qimaging, Surry, Canada). 
Binding of LL-37 and apo-A1 by surface plasmon resonance. The SPR 
experiments were performed using a BIACORE 3000 instrument (GE Healthcare). 
The N-HisTag containing ApoA1 (NH-ApoA1) was immobilized on the surface of a 
NTA  sensor chip (GE Healthcare ) according to manufacturer’s protocol. Shortly, for 
direct capture of NH-ApoA1, the surface of NTA chip was prepared by 1 min 
injection of 0.5 mM NiCl2, then NH-ApoA1 at concentration of 2,5 µg/ml diluted 
in running buffer (10 mM HEPES, 150 mM NaCl, and 0.005% surfactant (v/v), pH 
7.4) was injected with a flow rate of 5 μl/min to achieve capture level between 800-
1000 resonance units (RU). The surface stabilized ApoA1was primed with running 
buffer before subsequent assay steps. The binding of all LL-37 analogs were each 
tested in triplicate in concentration range up to 1000 nM in running buffer. All 
samples were injected at a flow rate of 5 μl/min. Between experiments, the surfaces 
were strictly regenerated with two pulses (30 s) of 1 M NaCl at a flow rate of 20 
μl/min, followed by an extensive wash procedure with running buffer. All 
measurements were performed at a constant temperature of 25 °C. Sensorgrams 
corrected for the reference were aligned, and a blank run was subtracted. 
 
 
 
Results 
 11 
LL-37 undergoes rapid carbamylation, which affects the peptide structure. 
Multiple studies based on circular dichroism [23], Fourier Transform Infrared [26] 
and NMR spectroscopy [27] reveal that LL-37 exists as a linear cationic, amphipathic 
α-helical structure within vesicles, both within the lipid bilayer and in solutions with 
an ionic composition resembling that of intracellular fluid or plasma. We used mass 
spectrometry to show that LL-37 undergoes rapid modification in the presence of 
cyanate, with the number of carbamylated residues increasing in a concentration- and 
time-dependent manner (Fig. 1A–D). In the presence of 10 mM KCNO (equivalent to 
cyanate levels found in the inflammatory milieu), multiple forms of carbamylated LL-
37 were detected in the reaction mixture after only 10 minutes. Closer analysis of the 
elution pattern of modified peptides from a RP-HPLC column revealed two distinct 
forms of LL-37 bearing a single homocitrulline, which were the most commonly 
detected modifications. Although almost 70% of the modifications were represented 
by a single site substitution, a variety of peptides carrying multiple (two, three or 
four) carbamylated residues (Fig. 1B) were also detected. Increasing either the 
cyanate concentration (to 50 mM and 100 mM) or incubation time shifted the 
modification pattern. In 50 mM KCNO, previously predominant peptides bearing a 
single modification were replaced by peptides bearing multiple carbamylations on 
different Lys residues, resulting in a highly heterogeneous mixture. Peptides of the 
same molecular mass bearing one or more carbamylated amino groups resolved into 
several peaks (same color in Fig. 1C), which depended on the particular combination 
of the amino groups modified. This suggests that all six lysine side chains in LL-37 
were equally susceptible to carbamylation. This was confirmed by analysis of LL-37 
in the presence of 100 mM cyanate, which showed the presence a of a hetrogenous 
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population of LL-37 with both 5 and 6 carbamylations (Several peaks with same 
colour Fig. 1C).  
To address the functional significance of LL-37 carbamylation, we focused 
our attention on modifications identified after incubating the peptide in an 
environment mimicking that of the inflammatory milieu. To this end, we first 
identified the most common carbamylated variants of LL-37 under these conditions. 
KCNO-treated samples were digested with S. aureus protease V8 and analyzed by 
LC-MS/MS. By calculating the number of spectra matching the identified peptides 
(spectral count), we showed that LL-37 bearing a carbamylated N-terminus (α-
carbamyl-Leu-1 LL-37; LL37C1) was the predominant peptide form present after 1 h 
of exposure to 10 mM KCNO. The second most common single-modified peptide was 
LL-37 bearing homocitrulline residue at position 8 (LL37C8) (Fig. 1D). 
Prolonged incubation with KCNO generated a mixture of LL-37 peptide 
derivatives containing homocitrulline at random positions. Among them, LL-37 
bearing a double modification (on Lys-12 and Lys-15; LL-37C12,15) was frequently 
detected (data not shown). Based on these results, LL37C1, LL-37C8, and LL-37C12,15 
were synthesized for further analysis (Table1).  
 In aqueous solution, LL-37 forms a random coil structure, but adopts an α-
helical conformation under physiological conditions; the α-helical structure is also 
adopted in TFE or lipid bilayer vesicles [26]. In the latter case, NMR studies show 
that LL-37 comprises three basic parts: an N-terminal α-helix, a C-terminal α-helix, 
and a C-terminal tail [27]. The hydrophobic surface of LL-37 is bordered by 
positively charged residues, which enable interaction with negatively charged 
molecules or structures such as LPS [28], genetic material, and bacterial cell wall 
components [13,14]. We hypothesized that carbamylation-induced changes in charge 
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and hydrophobicity would have a significant impact on the secondary structure of the 
peptide and, consequently, its biological activity (which is strictly related to the 
physiochemical properties of the peptide). We used CD spectroscopy to examine the 
impact of carbamylation on the capacity of LL-37 to form a helical structure. The far 
UV CD spectrum of LL-37 in a physiological salt solution resembling blood plasma 
showed two minima (at 208 and 222 nm) (Fig. 2A). These are characteristic for an α-
helical secondary structure. Interestingly, neither single carbamylation of Lys-8 (LL-
37C8) nor double carbamylation of Lys-12 and Lys-15 (LL-37C12,15) had any impact 
on the α-helical structure of LL-37. Conversely, carbamylation of the N-terminal 
amino group (LL37C1) led to a significant increase in the propensity of the peptide to 
adopt an α-helical structure (Fig. 2A).  
As expected, incubation with TFE increased the ellipticity and the helical 
content of the peptides beyond that observed in plasma buffer (Fig. 2B). Under these 
conditions, CD analysis of the far UV spectra predicted an α-helical content of 
approximately 80% for LL37C1, but approximately 50% for the native peptide (Fig. 
2B). However, the difference between the peptides in TFE was similar to that 
observed in plasma buffer, i.e., the α-helical composition of LL37C1 was about 30% 
greater than that of the other peptides (Fig. 2C). 
 
Carbamylation abrogate the bactericidal capacity of LL-37.  
LL-37 interacts with bacteria via electrostatic and hydrophobic interactions resulting 
in membrane permeabilisation and disruption. A broth micro-dilution assay revealed 
that the bactericidal activity of LL-37 was profoundly affected by carbamylation. At a 
peptide concentration of 1 μg/ml (i.e., 0.2 μM), LL37C8 and LL37C12,15 demonstrated 
impaired ability to inhibit bacterial growth of B. subtilis when compared with the 
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native peptide (p < 0.05 and p < 0.001, respectively; Figure 3A). Additionally, the 
potential of LL37C12,15 to inhibit the growth of E. coli (p < 0.001; Fig. 3B) and S. 
aureus (p < 0.05; Fig. 3C) was significantly decreased as compared to native LL-37.  
Confirming previous observations, that reducing the number of residues on the N 
terminus of LL-37 had only minor impact on its bactericidal properties, carbamylation 
of the N-terminal amino group did not affect the antimicrobial capacity of LL37C1 as 
compared to that of the native peptide (Fig. 3A – C). In addition to its direct 
microbicidal role, LL-37 is a potent regulator of innate immunity, controlling the 
response to pathogen-associated molecular patterns including endotoxin (LPS). 
Electrostatic interaction of the cationic LL-37 with the strongly anionic Lipid A 
domain of LPS prevents it from binding to TLR receptors expressed by monocytes 
and macrophages, a keystone event in inflammatory response. Therefore, we 
investigated whether carbamylation, and thus conversion of cationic Lys residues into 
neutral homocitrulline in LL-37 will affect the capacity of LPS to stimulate cells. 
hMDMs were exposed to LPS (100 ng/ml) in the presence of the either native LL-37 
or carbamylated peptides. Thereafter, the cytokine profile of the supernatants was 
examined by multiplex analysis. LL-37C1 and LL-37C8 attenuated the pro-
inflammatory activity of LPS and blocked secretion of TNF-α and IL-6 from the cells 
as effectively as the native peptide. Interestingly, we observed statistically significant 
decrease of TNF-α and IL-6 in supernatants from LPS stimulated macrophages in the 
presence of LL-37C12,15 as compared to the native peptide (Fig.4A, B). This may 
indicate that, as compared to the native peptide, LL-37C12,15 exhibits higher affinity for 
endotoxin thereof limiting it's binding to the TLR4 receptors.   
 
Carbamylation of LL-37 affects its affinity for Apo-A1.  
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In vivo, LL-37 circulates in a complex with Apo-A1 [24]. This carrier protein might 
function as a scavenger to inhibit the cytotoxic effects of the peptide secondary to its 
release at inflammatory sites. Therefore, we used surface plasmon resonance to 
examine whether carbamylation alters the affinity of LL-37 for Apo-A1, which would 
effectively modulate the concentration of the bioavailable peptide within the 
inflammatory milieu. We found that Lys-12 and Lys-15 are critical for the interaction 
between the peptide and Apo-A1. LL-37C12,15 showed a 3-fold lower affinity for Apo-
A1 than the native peptide. By contrast, both peptides carrying a single modification, 
LL-37C8 and LL-37C1, showed significantly stronger binding (1.5 and 3 times higher, 
respectively) than native LL-37. Taken together, these data indicate that any 
interference with the charged side chains of the amino acids within the LL-37 
polypeptide chain has a significant impact on the peptide’s ability to associate with its 
carrier protein. This may either reduce or amplify the observed in vivo effects by 
modulating the amount of accessible LL-37 in the environment (Fig. 5). 
 
Carbamylation affects the chemotactic capacity of LL-37.  
The ability of neutrophils to efficiently reach sites of inflammation is pivotal for 
efficient elimination of pathogens and restriction of potential tissue damage. LL-37 is 
a strong chemoattractant for neutrophils, monocytes, and T cells via the FPRL1 
receptor [15]. To investigate how carbamylation impacts the chemotactic activity of 
LL-37, we used a “state of the art” approach that allowed us to observe cell migration 
in real time. The Insall chambers used in the study provide a gradient for the cells to 
migrate against, rather than simply exposing cells to the chemoattractant alone. This 
in turn allows observation of cell migration in more detail as information about speed 
(average speed of the cell over time in any direction), velocity (average speed of the 
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cell in the direction of the gradient over time), and the directional accuracy of 
chemotaxis (expressed as the chemotactic index) can be obtained. We found that a 
peptide concentration of 20 μM was optimal in our assay (tested concentrations, 10 
μM–40 μM; data not shown). Both native LL-37 and the carbamylated forms induced 
neutrophil migration without any apparent toxicity (Fig. 6A, B, C). However, 
neutrophils were significantly less responsive to the carbamylated versions of LL-37. 
Both the speed and velocity of migrating neutrophils were significantly lower when 
LL37C1, LL37C8, and LL37C12,15 were used as chemoattractants. Interestingly, LL37C1 
was not only a significantly weaker chemoattractant than the other carbamylated 
peptides, but it also showed lower directional accuracy. Taken together, these 
observations suggest that, although all of the homocitrullinated peptides were able to 
trigger cell migration, carbamylation of the N-terminal amino group had a strong 
negative effect on directional accuracy.  
 
Carbamylation affects the cytotoxicity of LL-37.  
LL-37 can be cytotoxic to host cells. Therefore, we used a highly sensitive hemolytic 
assay to examine the impact of carbamylation on the cell-permeabilizing effects of 
LL-37. Human red blood cells (hRBC) were incubated with the peptide for 2 h at 
37°C. The results showed that LL37C1 exerted a very strong and concentration-
dependent lytic effect. The peptide caused a significant increase in hemoglobin 
release when used at a concentration of 2 μM (# p < 0.05; Fig. 7) as compared to PBS. 
The half-maximal effective concentration for LL37C1 was 17.9 μM. Conversely, 
LL37C8 and LL37C12,15 had significantly less capacity to induce membrane 
permeabilization (Fig. 7); indeed, hRBC were resistant to permeabilization by 
LL37C12,15 at concentrations of up to 20 μM. Given that the concentration of LL-37 
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can easily reach 20 μM at sites of inflammation (with levels up to 250 μM reported in 
psoriatic lesions) [29], permeabilization of membranes might facilitate the 
extracellular release of various potentially deleterious substances from lysed cells, 
which may then activate neutrophils and eventually lead to further increases in 
carbamylation. 
 
Discussion 
Host antimicrobial peptides, in particular LL-37, are potential novel therapeutics, 
mainly due to their wound healing, antiseptic, and antimicrobial properties[14,30,31]. 
In the era of rapidly increasing drug resistance among pathogens, novel treatments 
based on LL-37-derived peptides are very much needed. In addition, the 
immunostimulatory and cytotoxic properties of LL-37 may be useful tools for cancer 
treatment [32], or even as a vaginal contraceptive [33]. It is, however, important to 
keep in mind that the effector functions of LL-37 are most often executed at local 
sites of inflammation, and mainly in the context of neutrophil activation and 
subsequent release of MPO and H2O2 [34]. Thus, LL-37 is mainly present in 
microenvironments that foster carbamylation. Therefore, it is important to examine 
the impact of carbamylation on the immunomodulatory and cytotoxic functions of 
LL-37 prior to the clinical administration of cathelicidin-derived peptides. Here, we 
explored the effects of carbamylation on the biological functions of LL-37. 
We found that in the presence of cyanate, LL-37 undergoes rapid modification 
to generate a pool of peptides, each with a diverse carbamylation pattern. Mass 
spectrometry analyses revealed that the N-terminal amino group of leucine residues is 
highly reactive and is modified almost instantaneously in the presence of 10 mM 
KCNO. Thus, LL37C1 is most likely the predominant form of carbamylated LL-37 in 
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vivo. Even though carbamylation at this site did not affect the bactericidal properties 
of the peptide, LL-37C1 lost the ability to function as a chemoattractant for 
neutrophils. Concurrently, LL-37C1 gained significant RBC-lysing capacity; indeed, it 
was almost 3-fold more cytotoxic than native LL-37 in a hemolytic assay. Because 
tissue injury/necrosis results in increased receptor-dependent immune cell migration 
in response to released intracellular components[35,36], we cannot rule out the 
possibility that LL37C1 indirectly triggers cell migration in vivo in response to damage 
to surrounding tissue. By stark contrast, although the chemoattractive capacity of LL-
37C8 and LL-37C12,15 was diminished, neutrophils retained directional accuracy in 
response to the stimuli. This suggests that, despite the reduced affinity of Lys-8 and 
Lys-12/Lys-15 carbamylated peptides for FPRL-1, they were still able to bind the 
receptor. At the same time, LL-37C8 and LL-37C12,15 were significantly less toxic to 
hBRCs, with the latter exhibiting no hemolytic effects at a concentration of 20 μM. 
This observation confirms those of previous studies showing that truncation or 
blocking [26] of the N-terminus reduces the cytotoxicity of LL-37 while at the same 
time leaving bactericidal activity unchanged [37]. Indeed, only LL-37C12,15 showed 
lower bactericidal activity than the native peptide against B. subtilis, E. coli, and S. 
aureus. In addition, Xhindoli and colleagues showed that oligomerization of LL-37 
results in increased formation of α-helices, leading to an increased capacity to 
permeabilize erythrocytes and monocytes; this suggests that a parallel arrangement of 
the peptides favors aggregation via interaction between the N-termini [26]. In 
agreement with these results, we showed that LL37C1 was about 50% more α-helical 
than the native peptide, both in a secondary structure-inducing environment (50% 
TFE buffer) and in a plasma-mimicking buffer. Since loss of the N-terminal charge 
due to carbamylation increases the hydrophobicity of this region [38], it is possible 
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that LL37C1 is more prone to aggregation due to reduced electrostatic repulsion 
between the molecules. This would increase its propensity to form α-helices and 
explain the increased cytotoxicity. Intriguingly, the ability of LL-37C8 and LL-37C12,15 
to lyse neutrophils and erythrocytes was different. Neutrophil membranes are 
zwitterionic and interact with LL-37 independently of the overall charge of the 
peptide [22,39]. By contrast, the erythrocyte membrane contains sialic acid, which 
results in a negatively charged cell surface; therefore, it is more susceptible to lysis by 
cationic peptides. Thus, it is not surprising that the reduced cationicity conferred by 
carbamylation results in impaired hemolysis but does not affect the lysis of 
neutrophils. Interestingly, this difference was not evident in the case of LL37C1. 
However, the uncompromising capacity of LL37C1 to lyse both erythrocytes and 
neutrophils (data not shown) emphasizes the involvement of a hydrophobic N-
terminus in this process. 
The antimicrobial and cytotoxic activities of LL-37 are effectively inhibited in 
human plasma. This latency is due to the interaction between LL-37 and its carrier 
protein, apoA-1 [24]; this interaction is dependent on the hydrophobicity of the N-
terminus of LL-37 [40] as well as on its α-helical content [41]. In line with these 
results, we found that LL37C1 showed significantly higher affinity for apo-A1 (300%) 
than the native peptide, indicating that the cytotoxic effects of LL37C1 may be limited 
by an Apo-A1-dependent protective mechanism. However, LL37C1 may be 
detrimental to the host if generated at inflammatory foci that are poorly infiltrated by 
blood plasma. By contrast, LL37C12,15 had lower affinity for apo-A1. Since Apo-A1 
has a net negative charge [42], it is likely that the significant loss of electrostatic 
interactions upon carbamylation of two or more Lys residues impairs L-37 binding to 
apo-A1.  
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Upon carbamylation, the bactericidal activity of LL-37 is compromised. 
Again, this is most likely related to the loss of two positive charges when Lys residues 
are converted to homocitrulline. It is likely that the reduced electrostatic attraction 
between LL-37C12,15 and bacterial membranes results in impaired antimicrobial 
activity against B. subtilis, E. coli, and S. aureus. Interestingly, even though the 
bactericidal domain of LL-37 has been mapped to the C-terminal region (amino acids 
17–29) [43], LL-37C8 showed impaired bactericidal activity against B. subtilis. Thus, 
the lysine at position 8 is important for efficient killing of this Gram-positive 
bacterium.   
Interestingly, LL-37C12,15 was the most effective LPS-detoxifying agent among 
all tested forms of LL-37, i.e., this carbamylated peptide efficiently attenuated the 
LPS-induced production of TNF-α, an important mediator of endotoxic shock [44]. In 
addition to directly binding LPS via electrostatic and hydrophobic interactions, LL-37 
also interacts with the LPS receptor, CD14, to block LPS-induced macrophage 
activation [45]. We hypothesize that carbamylation of Lys-12 and Lys-15 increases 
the binding of LL-37 to this receptor. From a clinical point of view, it is tempting to 
speculate that LL37C12,15 provides therapeutic protection against septic shock without 
being cytotoxic. Nevertheless, it must be kept in mind that further carbamylation may 
alter the biological activity of the peptide. 
In summary, carbamylation has a profound impact on the bactericidal, 
cytotoxic, and pro-inflammatory activity of LL-37, which may have detrimental 
consequences for the host. The pattern of carbamylation is dependent on the OCN− 
concentration and time of exposure, suggesting that the subsequent effects of this 
modification will be difficult to foresee and, therefore, control in vivo. Thus, we 
suggest that caution should be exercised when administering cathelicidin-derived 
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peptides to patients with diseases manifested by inflammation, such as severe 
infections or sepsis. 
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Tables and Figures 
Table 1. LL-37 peptides synthesized and examined in this study. 
Peptide Amino acid sequence 
LL-37 LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES 
LL-37C1 (α-carb-L)LGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES 
LL-37C8 LLGDFFR(ε-carb-K)SKEKIGKEFKRIVQRIKDFLRNLVPRTES 
LL-37C12,15 LLGDFFRKSKE(ε-carb-K)IG(ε-carb-K)EFKRIVQRIKDFLRNLVPRTES 
α-carb-L, leucine carbamylated on the α-carbon; ε-carb-K, lysine carbamylated on the 
ε -carbon.   
Figure 1. The number of carbamylated amino acid residues increases with 
KCNO concentration. LL-37 was incubated for 3 h with increasing amounts of 
KCNO. (A) 0 mM, (B) 10 mM, (C) 50 mM. The samples were then analyzed by 
liquid chromatography (LC)-MS/MS and the m/z values corresponding to LL-37 
bearing 0–7 carbamylated amino acid residues were extracted (see legend for color 
code). KCNO-mediated carbamylation results in a heterogeneous population of 
carbamylated LL-37 peptides, as evidenced by the appearance of multiple peaks. (D) 
The N-terminal leucine (L1) and the lysine at position 8 within LL-37 are highly 
accessible for carbamylation. LL-37 was incubated with 10 mM or 50 mM KCNO for 
1 h at 37°C. The position of the modifications was determined using NanoESI-
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MS/MS after V8 digestion. Spectral counts were calculated by summing the number 
of spectra matching the identified peptides. 
Figure 2. CD spectra of native and carbamylated LL-37. The peptide 
concentration was 10 μM. The TFE buffer comprised 50% TFE in 10 mM sodium 
phosphate buffer. The plasma buffer contained 113 mM NaCl, 24 mM NaHCO3, 0.6 
mM MgCl2, 1.3 mM CaCl2, and 3.9 mM KCl. (A) Spectra represent the mean of two 
(50% TFE buffer) or three (plasma buffer) independent experiments. (B) Differences 
in the predicted α-helical content of the peptide analogues in 50% TFE buffer at 190–
260 nm. (C) Difference in the predicted α-helical content of the peptide analogues in 
plasma buffer at 190–260 nm. (B–C) Data are expressed as the mean ± SD. Statistical 
significance was evaluated by one-way ANOVA, followed by Tukey’s multiple 
comparison test. p < 0.05, **p < 0.01, and ***p < 0.001. TFE, trifluoroethanol. 
 
Figure 3. Carbamylation abrogates the antimicrobial activity of LL-37. (A–C) 
The number of colony-forming units formed after incubation with (A) B. subtilis, (B) 
E. coli, and (C) S. aureus. All bacterial species were incubated with carbamylated or 
native LL-37. Bacterial growth in the presence of native LL-37 was set to 100%. Data 
are expressed as the mean ± SD. Statistical significance was evaluated by one-way 
ANOVA, followed by Tukey’s multiple comparisons post-test. *p < 0.05, **p < 0.01, 
and ***p < 0.001; and #p < 0.05, ##p < 0.01, and ###p < 0.001 compared with 
negative control (broth). 
Figure 4. LPS induced cell activation remain supressed in the presence of 
carbamylated LL-37. Human monocyte-derived macrophages were incubated with 
100 ng/ml LPS in the absence or presence of modified peptides. The levels of (A) 
TNF-α and (B) IL-6 in the supernatants were then measured. LL-37+LPS was set at 
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100%. Data are expressed as the mean ± SD. Statistical significance was evaluated by 
one-way ANOVA, followed by Tukey’s multiple comparisons post-test. *p < 0.05, 
**p < 0.01, and ***p < 0.001; and #p < 0.05, ##p < 0.01, and ###p < 0.001, 
compared with LPS. 
Figure 5. Carbamylation of LL-37 reduces its affinity for apolipoprotein A1. 
Surface plasmon resonance curves showing the interaction between Apo-A1 and 
carbamylated and native LL-37 at a concentration of 1 μM. RU, resonance units. 
Figure 6. Carbamylation reduces the chemotactic potential of LL-37. Analysis of 
chemotaxis at a peptide concentration of 20 μM. Neutrophils from four healthy 
volunteers were treated with either native or modified peptide. Values for speed, 
velocity, chemotactic index, and the resultant vector length were analyzed. The 
midline of each box represents the median value. Statistical significance was 
evaluated by one-way ANOVA, followed by Tukey’s multiple comparisons post-test: 
*p < 0.05, **p < 0.01, and ***p < 0.001; and #p < 0.05, ##p < 0.01, and ###p < 
0.001, compared with the native peptide. 
 
Figure 7. Carbamylation significantly affects the hemolytic capacity of LL-37. 
Erythrocytes were incubated for 2 h with each LL-37 analogue at concentrations 
ranging from 1–20 μM. The hemolytic activity of the peptides was evaluated by 
recording the release of hemoglobin from human erythrocytes at 405 nm. Data are 
representative of four individual experiments and are expressed as the mean ± SD. 
Statistical significance was evaluated by one-way ANOVA, followed by Dunnett’s 
multiple comparisons post-test: *p < 0.05, **p < 0.01 and ***p < 0.001, compared 
with LL-37. # p < 0.05 in case of LL-37C1 as compared with PBS. 
